Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Rigel Pharmaceuticals Inc patents


Recent patent applications related to Rigel Pharmaceuticals Inc. Rigel Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Rigel Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Rigel Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Rigel Pharmaceuticals Inc-related inventors


Compositions and methods for inhibition of the jak pathway

Disclosed are compounds of formula i, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the jak pathway or inhibition of jak kinases, particularly jak 2 and jak3, are therapeutically useful. Also disclosed are methods of making the compounds.. ... Rigel Pharmaceuticals Inc

Antigen binding molecules to tigit

Provided herein are antigen binding molecules that bind to tigit, include antibodies and antigen binding fragments thereof.. . ... Rigel Pharmaceuticals Inc

Prodrugs of 2,4-pyrimidinediamine compounds and their uses

The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.. . ... Rigel Pharmaceuticals Inc

Tgf-ß inhibitors

. . Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and n-oxides thereof (and solvates and hydrates thereof), wherein a, x, z, m, p, and r2 are as described herein. ... Rigel Pharmaceuticals Inc

Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lupus erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.. ... Rigel Pharmaceuticals Inc

Fumarate analogs and uses thereof

Aspects of the present disclosure include compounds that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.. ... Rigel Pharmaceuticals Inc

Method and device for administering xinafoate salt of n4-(2,2-difluoro-4h-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-n2-[3-(methylaminocarbonylmethyleneoxy)phenyl]2,4-pyrimidinediamine

Disclosed embodiments concern a device for administering a xinafoate salt of n4-[(2,2-difluoro-4h-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-n2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine, or compositions thereof, and a method for making and using the device. Particular disclosed embodiments concern formulating the xinafoate salt for administration via the device.. ... Rigel Pharmaceuticals Inc

Protein kinase c inhibitors and uses thereof

. . . . This disclosure concerns compounds which are useful as inhibitors of protein kinase c (pkc) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of pkc. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.. ... Rigel Pharmaceuticals Inc

Tetrazolones as a carboxylic acid bioisosteres

. . The present disclosure provides compounds that include a tetrazolone derivative of a carboxyl group of an active agent. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.. ... Rigel Pharmaceuticals Inc

Protein kinase c inhibitors and uses thereof

. . This disclosure concerns compounds which are useful as inhibitors of protein kinase c (pkc) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of pkc. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.. ... Rigel Pharmaceuticals Inc

Prodrugs of 2,4-pyrimidinediamine compounds and their uses

. . The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.. . ... Rigel Pharmaceuticals Inc

2,4-pyrimidinediamine compounds and their uses

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the ige and/or igg receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the ige and/or igg receptor signaling cascades.. . ... Rigel Pharmaceuticals Inc

Nrf2 activating compounds and uses thereof

Aspects of the present disclosure include compounds that activate nrf2. Such compounds may find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. ... Rigel Pharmaceuticals Inc

Nrf2 activating compounds and uses thereof

Aspects of the present disclosure include compounds that activate nrf2. Such compounds find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. ... Rigel Pharmaceuticals Inc

06/08/17 / #20170158683

Compositions and methods for inhibition of the jak pathway

Disclosed are compounds of formula i, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the jak pathway or inhibition of jak kinases, particularly jak 2 and jak3, are therapeutically useful. Also disclosed are methods of making the compounds.. ... Rigel Pharmaceuticals Inc

06/01/17 / #20170152246

Protein kinase c inhibitors and uses thereof

This disclosure concerns compounds which are useful as inhibitors of protein kinase c (pkc) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of pkc. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.. ... Rigel Pharmaceuticals Inc

06/01/17 / #20170151239

2,4-pyrimidinediamine compounds and their uses

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the ige and/or igg receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the ige and/or igg receptor signaling cascades.. . ... Rigel Pharmaceuticals Inc

05/18/17 / #20170137411

Compositions and methods for inhibition of the jak pathway

Disclosed are compounds of formula i, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the jak pathway or inhibition of jak kinases, particularly jak 2 and jak3, are therapeutically useful.. . ... Rigel Pharmaceuticals Inc

05/11/17 / #20170129862

Tetrazolones as a carboxylic acid bioisosteres

The present disclosure provides compounds that include a tetrazolone derivative of a carboxyl group of an active agent. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.. ... Rigel Pharmaceuticals Inc

05/04/17 / #20170121291

Compositions and methods for inhibition of the jak pathway

The invention encompasses compounds having formula i and the compositions and methods using these compounds in the treatment of conditions in which modulation of the jak pathway or inhibition of jak kinases, particularly jak3, are therapeutically useful.. . ... Rigel Pharmaceuticals Inc

04/06/17 / #20170096409

2,3-disubstituted pyridine compounds as tgf-beta inhibitors and methods of use

The invention described herein comprises compounds of formula (iv) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (iv) inhibit signaling by a member of the tgf-β superfamily such as nodal or activin.. ... Rigel Pharmaceuticals Inc

03/23/17 / #20170081290

2,4-pyrimidinediamine compounds and their uses

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the ige and/or igg receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the ige and/or igg receptor signaling cascades.. . ... Rigel Pharmaceuticals Inc

03/09/17 / #20170065569

Fumarate analogs and uses thereof

Aspects of the present disclosure include compounds that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.. ... Rigel Pharmaceuticals Inc

02/16/17 / #20170042891

Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer

This invention is directed to methods of preventing, treating or managing cancer, preferably metastatic cancer, in a patient. The methods comprise administering an effective amount of an axl inhibitor in combination with the administration of an effective amount of one or more chemotherapeutic agents.. ... Rigel Pharmaceuticals Inc

02/09/17 / #20170037041

Benzazole compounds and methods for making and using the compounds

Disclosed are novel benzazole compounds and compositions comprising the compounds. The compounds are useful as kinase inhibitors including interleukin receptor associated kinases (irak) inhibitors. ... Rigel Pharmaceuticals Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Rigel Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Rigel Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###